

# Biomarkers Market worth \$78.1 billion in 2026 - Exclusive Report by MarketsandMarkets™

*North America accounted for the largest share of the biomarkers market in 2020.*

NORTHBROOK, IL, USA, March 25, 2022  
/EINPresswire.com/ -- According to the new market research report

"[Biomarkers Market](#) by Product

(Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global

Forecast to 2026", published by MarketsandMarkets™, the global Biomarkers Services Market is expected to reach USD 78.1 billion in 2026 from USD 43.1 billion in 2021 at a CARG of 12.6%.



Browse in-depth TOC on "Biomarkers Market"

244 – Tables

40 – Figures

238 – Pages

Download PDF Brochure: <https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43>

The Growth in the biomarkers services market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, growing funding activities for biomarker research, and product innovations.

The infectious diseases segment accounted for the largest share of the disease indication segment in the biomarkers market in 2020.

Based on disease indication, the market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2020, the infectious diseases segment accounted for the largest share of the

market. The large share of this segment can be attributed to the growing prevalence of infectious diseases, coupled with the outbreak of the COVID-19 pandemic.

The efficacy biomarkers segment accounted for the largest share of the type segment in the biomarkers market in 2020.

Based on type, the biomarkers services market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. In 2020, the efficacy biomarkers segment accounted for the largest share of the global market. The large share of this segment can be attributed to the ability of these biomarkers to evaluate the therapeutic efficacy of drug products.

Request Sample Pages: <https://www.marketsandmarkets.com/requestsampleNew.asp?id=43>

The Asia Pacific region is the fastest-growing region of the biomarkers market in 2020.

In 2020, the Asia Pacific region accounted for the fastest growing region of the market. The growth of this segment is primarily due to the increasing use of biomarkers for diagnostic purposes, the growing prevalence of chronic diseases, favorable government initiatives, and the growing focus on genomic & proteomic research projects.

Some of the leading players operating in the biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).

Mr. Aashish Mehra  
MarketsandMarkets™ INC  
+1 888-600-6441

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/566532629>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.